# A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

Source: https://onco.cc/trials/nct05716087/  
OnCo record `nct05716087` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rocbrutinib in mantle cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., active and no longer recruiting.

## Summary

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT05716087 by Guangzhou Lupeng Pharmaceutical Company LTD., with 62 participants planned, started 2023-02-21 and due to reach its primary completion in 2024-12-05. Interventions recorded: Rocbrutinib. Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05716087
- Phase: 2
- Setting: An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of Rocbrutinib Monotherapy for Recurrent or Refractory Mantle Cell Lymphoma
- Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
- Enrolled: 62

## Sources

- ClinicalTrials.gov NCT05716087: https://clinicaltrials.gov/study/NCT05716087

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Rocbrutinib](https://onco.cc/drugs/rocbrutinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05716087.json